CDX-1401: Preliminary Phase I/II data

Preliminary data from an ongoing, open-label, dose-escalation, U.S. Phase I/II trial in 20 patients, 35% of which had confirmed NY-ESO-1 expression, showed that subcutaneous CDX-1401 plus resiquimod as an adjuvant produced 6 cases of stable diseases for up to 11.5 months. The combination was well tolerated with no dose-limiting toxicities reported. Additionally, 39% of patients had increases in NY-ESO-1-specific T cell responses. Resiquimod is a toll-like receptor 7 (TLR7) and TLR8 agonist. Data were presented at the International Society of Biological Therapy of Cancer meeting in Washington. ...